Company news
Viatris Inc. (NASDAQ:VTRS) news
Viatris Inc. news releases on 6ix. Latest, Aug 5, 2025: Viatris Announces Appointment of David Simmons to the Company's Board of Directors
Press releases — page 2
Viatris Announces Appointment of David Simmons to the Company's Board of Directors
August 4, 2025
Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference
July 31, 2025
Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis
July 17, 2025
Viatris Certified as a Great Place to Work® in Canada
July 15, 2025
Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia
June 25, 2025
Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025
June 11, 2025
Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions
June 1, 2025
Viatris Announces Launch of First Clozapine Orally Disintegrating Tablet (ODT) in Canada
May 27, 2025
Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook
May 7, 2025
Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain
May 7, 2025
Viatris Announces Positive Results from Phase 3 Study of Investigational XULANE LO™ Low Dose Patch for Birth Control in Women of Childbearing Potential
May 7, 2025
Viatris Announces Appointments of Frank D'Amelio and Michael Severino, M.D., to the Company's Board of Directors
May 4, 2025
Viatris to Present at the BofA Securities 2025 Healthcare Conference
April 24, 2025
Viatris Files Supplemental New Drug Applications to Japan's Ministry of Health, Labor and Welfare for the Approval of EFFEXOR® for the Treatment of Generalized Anxiety Disorder
April 20, 2025
Viatris Appoints Hemanth J. Varghese as Chief Strategy Officer
April 13, 2025
Viatris Statement on Nationwide Settlement to Resolve Opioid-Related Claims
April 6, 2025
Viatris to Report First Quarter 2025 Financial Results on May 8, 2025
March 27, 2025
Viatris to Present at the Barclays 27th Annual Global Healthcare Conference
March 4, 2025
Viatris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Financial Guidance
February 26, 2025
Viatris Maintains Dividend Policy for 2025 and Announces Quarterly Dividend
February 26, 2025
Viatris to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
February 2, 2025
Viatris to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 6, 2025
Viatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet Rheumatology
December 17, 2024
Viatris Reports Third Quarter Financial Results for 2024
November 6, 2024
Viatris Announces Third Quarter 2024 Dividend
November 4, 2024
Viatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare Conference
October 28, 2024
Viatris Named to Forbes' World's Top Companies for Women 2024 List
October 28, 2024
Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe
October 15, 2024
Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe
October 15, 2024
Viatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR® in Japanese Adults with Generalized Anxiety Disorder (GAD)
October 8, 2024
Viatris Named to Forbes' Annual List of the World's Best Employers for the Fourth Year in a Row
October 7, 2024
Viatris Announces the Pricing Terms of Maximum Tender Offer
September 17, 2024
Viatris Announces Early Tender Results and Increase of Pending Maximum Tender Offer
September 16, 2024
Viatris to Report Third Quarter 2024 Financial Results on November 7, 2024
September 15, 2024
Viatris Announces the Pricing Terms of Pending Any and All Cash Tender Offers
September 9, 2024
Viatris Announces Expiration and Results of Any and All Cash Tender Offers
September 9, 2024
Viatris Announces Cash Tender Offers for Certain Outstanding Notes
September 3, 2024
Viatris Presents Late Breaking Abstract on Cenerimod at the 26th Asia-Pacific League of Associations for Rheumatology Annual Congress
August 22, 2024
Viatris Reports Second Quarter Financial Results for 2024
August 7, 2024
Viatris Announces Second Quarter 2024 Dividend
August 5, 2024
Viatris Brings to Completion All Previously Announced Divestitures With the Closing of its Over-the-Counter Business Divestiture
July 2, 2024
U.S. Department of Justice Informs Viatris That It No Longer Considers Mylan a Subject of Generic Drug Industry Antitrust Investigation
July 1, 2024
Viatris Named to TIME's World's Most Sustainable Companies 2024 List
June 24, 2024
Viatris to Report Second Quarter 2024 Financial Results on August 8, 2024
June 6, 2024
Viatris to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 3, 2024
Viatris Appoints Rogerio Vivaldi Coelho, M.D., to Board of Directors
June 2, 2024
Viatris to Participate in the Jeffries Global Healthcare Conference
May 30, 2024
Viatris Publishes 2023 Sustainability Report: Building Sustainable Access at Scale
May 20, 2024
Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges
May 8, 2024
Viatris to Participate in the BofA Securities 2024 Health Care Conference
May 1, 2024